160 related articles for article (PubMed ID: 36982671)
1. The SARS-CoV-2 Virus and the Cholinergic System: Spike Protein Interaction with Human Nicotinic Acetylcholine Receptors and the Nicotinic Agonist Varenicline.
Carlson EC; Macsai M; Bertrand S; Bertrand D; Nau J
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982671
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 spike ectodomain targets α7 nicotinic acetylcholine receptors.
O'Brien BCV; Weber L; Hueffer K; Weltzin MM
J Biol Chem; 2023 May; 299(5):104707. PubMed ID: 37061001
[TBL] [Abstract][Full Text] [Related]
3. Nicotinic Cholinergic System and COVID-19: In Silico Identification of an Interaction between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications.
Farsalinos K; Eliopoulos E; Leonidas DD; Papadopoulos GE; Tzartos S; Poulas K
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32823591
[TBL] [Abstract][Full Text] [Related]
4. Nicotinic cholinergic system and COVID-19: In silico identification of interactions between α7 nicotinic acetylcholine receptor and the cryptic epitopes of SARS-Co-V and SARS-CoV-2 Spike glycoproteins.
Lagoumintzis G; Chasapis CT; Alexandris N; Kouretas D; Tzartos S; Eliopoulos E; Farsalinos K; Poulas K
Food Chem Toxicol; 2021 Mar; 149():112009. PubMed ID: 33503469
[TBL] [Abstract][Full Text] [Related]
5. Procognitive effects of varenicline in the animal model of schizophrenia depend on α4β2- and α 7-nicotinic acetylcholine receptors.
Potasiewicz A; Golebiowska J; Popik P; Nikiforuk A
J Psychopharmacol; 2018 Dec; 33(1):269881118812097. PubMed ID: 30501536
[TBL] [Abstract][Full Text] [Related]
6. Functional interactions of varenicline and nicotine with nAChR subtypes implicated in cardiovascular control.
Rollema H; Russ C; Lee TC; Hurst RS; Bertrand D
Nicotine Tob Res; 2014 Jun; 16(6):733-42. PubMed ID: 24406270
[TBL] [Abstract][Full Text] [Related]
7. Nicotinic receptors as SARS-CoV-2 spike co-receptors?
Dormoy V; Perotin JM; Gosset P; Maskos U; Polette M; Deslée G
Med Hypotheses; 2022 Jan; 158():110741. PubMed ID: 34924680
[TBL] [Abstract][Full Text] [Related]
8. A Functional Interaction Between Y674-R685 Region of the SARS-CoV-2 Spike Protein and the Human α7 Nicotinic Receptor.
Chrestia JF; Oliveira AS; Mulholland AJ; Gallagher T; Bermúdez I; Bouzat C
Mol Neurobiol; 2022 Oct; 59(10):6076-6090. PubMed ID: 35859025
[TBL] [Abstract][Full Text] [Related]
9. Agonists or positive allosteric modulators of α7 nicotinic acetylcholine receptor prevent interaction of SARS-Cov-2 receptor-binding domain with astrocytoma cells.
Kalashnyk O; Lykhmus O; Sullivan R; Komisarenko S; Skok M
Biochem Biophys Res Commun; 2024 May; 709():149825. PubMed ID: 38537599
[TBL] [Abstract][Full Text] [Related]
10. A potential interaction between the SARS-CoV-2 spike protein and nicotinic acetylcholine receptors.
Oliveira ASF; Ibarra AA; Bermudez I; Casalino L; Gaieb Z; Shoemark DK; Gallagher T; Sessions RB; Amaro RE; Mulholland AJ
Biophys J; 2021 Mar; 120(6):983-993. PubMed ID: 33609494
[TBL] [Abstract][Full Text] [Related]
11. An experimental test of the nicotinic hypothesis of COVID-19.
Godellas NE; Cymes GD; Grosman C
Proc Natl Acad Sci U S A; 2022 Nov; 119(44):e2204242119. PubMed ID: 36279466
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological and molecular studies on the interaction of varenicline with different nicotinic acetylcholine receptor subtypes. Potential mechanism underlying partial agonism at human α4β2 and α3β4 subtypes.
Arias HR; Feuerbach D; Targowska-Duda K; Kaczor AA; Poso A; Jozwiak K
Biochim Biophys Acta; 2015 Feb; 1848(2):731-41. PubMed ID: 25475645
[TBL] [Abstract][Full Text] [Related]
13. Nicotinic cholinergic system and COVID-19:
Alexandris N; Lagoumintzis G; Chasapis CT; Leonidas DD; Papadopoulos GE; Tzartos SJ; Tsatsakis A; Eliopoulos E; Poulas K; Farsalinos K
Toxicol Rep; 2021; 8():73-83. PubMed ID: 33425684
[TBL] [Abstract][Full Text] [Related]
14. The Abeta1-42M35C mutated amyloid peptide Abeta1-42 and the 25-35 fragment fail to mimic the subtype-specificity of actions on recombinant human nicotinic acetylcholine receptors (alpha7, alpha4beta2, alpha3beta4).
Pym LJ; Buckingham SD; Tsetlin V; Boyd CA; Sattelle DB
Neurosci Lett; 2007 Oct; 427(1):28-33. PubMed ID: 17945421
[TBL] [Abstract][Full Text] [Related]
15. Cholinergic dysfunction in COVID-19: frantic search and hoping for the best.
Nadwa EH; Al-Kuraishy HM; Al-Gareeb AI; Elekhnawy E; Albogami SM; Alorabi M; Batiha GE; De Waard M
Naunyn Schmiedebergs Arch Pharmacol; 2023 Mar; 396(3):453-468. PubMed ID: 36460816
[TBL] [Abstract][Full Text] [Related]
16. SARS-Cov-2 spike protein fragment 674-685 protects mitochondria from releasing cytochrome c in response to apoptogenic influence.
Kalashnyk O; Lykhmus O; Izmailov M; Koval L; Komisarenko S; Skok M
Biochem Biophys Res Commun; 2021 Jul; 561():14-18. PubMed ID: 34000512
[TBL] [Abstract][Full Text] [Related]
17. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors.
Mihalak KB; Carroll FI; Luetje CW
Mol Pharmacol; 2006 Sep; 70(3):801-5. PubMed ID: 16766716
[TBL] [Abstract][Full Text] [Related]
18. Electrophysiological perspectives on the therapeutic use of nicotinic acetylcholine receptor partial agonists.
Papke RL; Trocmé-Thibierge C; Guendisch D; Al Rubaiy SA; Bloom SA
J Pharmacol Exp Ther; 2011 May; 337(2):367-79. PubMed ID: 21285282
[TBL] [Abstract][Full Text] [Related]
19. Prefrontal beta2 subunit-containing and alpha7 nicotinic acetylcholine receptors differentially control glutamatergic and cholinergic signaling.
Parikh V; Ji J; Decker MW; Sarter M
J Neurosci; 2010 Mar; 30(9):3518-30. PubMed ID: 20203212
[TBL] [Abstract][Full Text] [Related]
20. New insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice.
Bagdas D; Alkhlaif Y; Jackson A; Carroll FI; Ditre JW; Damaj MI
Neuropharmacology; 2018 Aug; 138():72-79. PubMed ID: 29860196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
